Chapter

Multiple cardiovascular risk intervention

Miles Fisher

in Type 2 Diabetes

Second edition

Published on behalf of Oxford University Press

Published in print May 2010 | ISBN: 9780199596171
Published online January 2012 | e-ISBN: 9780191739699 | DOI: http://dx.doi.org/10.1093/med/9780199596171.003.0059

Series: Oxford Diabetes Library

Multiple cardiovascular risk intervention

More Like This

Show all results sharing this subject:

  • Endocrinology and Diabetes

GO

Show Summary Details

Preview

• Cardiovascular disease is a common cause of morbidity and mortality in people with type 2 diabetes. Some guidelines define diabetes as a coronary heart disease equivalent, requiring multiple cardiovascular risk factor reduction • The treatment of hyperglycaemia in type 2 diabetes reduces cardiovascular events, and on long-term follow up reduces cardiovascular and total mortality. Metformin and pioglitazone have advantages in subgroups of patients • There is a large evidence base for the treatment of hypertension in people with type 2 diabetes, using multiple antihypertensive drugs, and for the use of statins. The results of studies of other lipid-regulating drugs have been disappointing • Benefits of other methods to reduce cardiovascular risk, such as antiplatelet drugs and antioxidants, have yet to be established in people with type 2 diabetes.

‘Diabetes is a state of premature cardiovascular death which is associated with chronic hyperglycaemia and may also be associated with blindness and renal failure.’ Miles Fisher, British Diabetic Association meeting Dublin, 1996.

Chapter.  4255 words.  Illustrated.

Subjects: Endocrinology and Diabetes

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.